Europe Non-Alcoholic Steatopatitis Market Forecast to 2028

Europe Non-Alcoholic Steatopatitis Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product (Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib, Cenicriviroc, and Others), Application (Treatment and Diagnosis), and Sales Channel (Hospital Pharmacy, Online Provider, and Retail Pharmacy)

Report Code : BMIRE00025404 | Region : Europe | Industry : Pharmaceuticals | Published Date : 18/Jul/2022

The Europe non-alcoholic steatopatitis market is expected to reach US$ 6,765.21 million by 2028 from US$ 496.83 million in 2021. The market is estimated to grow at a CAGR of 45.2% from 2021 to 2028.

Non-Alcoholic Steatopatitis is an under-recognized condition. Increasing awareness of this disease among the general public and primary care physicians (PCPs) is essential for a structured referral pathway and early detection. By establishing a clear patient pathway for referrals and patient awareness campaigns, more individuals can be identified and sent to specialists for further evaluation, thereby expanding the patient pool. To raise awareness of NASH, the NASH Education Program launched the public education campaign on June 12, 2018, on "International NASH Day" to raise awareness of the non-alcoholic fatty liver disease and its more advanced form NASH, which affects over ~115 million people. NASH 24X7, a digital platform aimed at raising exposure and awareness regarding the epidemic NASH, took a few steps on June 12, 2019, on International NASH Day, including HCP support, patient awareness, and press/TV release programs. In terms of patient education, NASH Crusaders of NASH 24X7 collaborated with HCPs across India to hold many small and large-scale awareness and education workshops on liver health and the necessity of a healthy lifestyle in preventing NAFLD/NASH. On International NASH Day, several efforts were made to reach the general public, such as press releases and television programs using digital and print media. The Europe non-alcoholic steatopatitis market is expected to grow at a good CAGR during the forecast period.

Europe Non-Alcoholic Steatopatitis Revenue and Forecast to 2028 (US$ Million)

Europe Non-Alcoholic Steatopatitis Market Segmentation

The Europe Non-Alcoholic Steatopatitis market segmented into product, application, sales channel, and country. Based on product type the Europe Non-Alcoholic Steatopatitis market is segmented into vitamin e and pioglitazone, ocaliva, elafibranor, selonsertib & cenicriviroc and others. The selonsertib & cenicriviroc segment is expected to be the fastest growing segment over the forecaste period .Based on application the Europe Non-Alcoholic Steatopatitis market segmented into treatment and diagnosis. The treatment segment is dominated Europe Non-Alcoholic Steatopatitis market in 2020. Based on sales channel the Europe Non-Alcoholic Steatopatitis market segmented into hospital pharmacy, online provider, and retail pharmacy. The retail pharmacy segment is dominated Europe Non-Alcoholic Steatopatitis market in 2020. Based on country, the Europe non-alcoholic steatopatitis market is segmented into Germany, the UK, France, Italy, Spain, and the rest of Europe. Germany dominated the Europe non-alcoholic steatopatitis market in 2020.

Cadila Pharmaceutical, Intercept Pharmaceutical, Novartis AG, Galmed Pharmaceutical, GENFIT, ONE WAY LIVER SI, BioPredictive S.A.S, Siemens Healthineers AG, and Laboratory Corporation of America Holdings are among the leading companies in the Europe non-alcoholic steatopatitis market are among the leading companies in the Europe non-alcoholic steatopatitis market.

Treatment Segment to Dominate Europe Non-Alcoholic Steatohepatitis market Forecast to 2028 during 2019-2028

According to a new market research study on the Europe Non-Alcoholic Steatohepatitis market Forecast to 2028 - by product, application, sales channel and countries is expected to reach US$ 12,963.42 million by 2028 from US$ 838.07 million in 2021. The market is estimated to grow at a CAGR of 47.9% from 2021 to 2028. The report provides trends prevailing in the Europe Non-Alcoholic Steatohepatitis market along with the drivers and restraints pertaining to the market growth . Rising prevalence of NASH is the major factor driving the growth of the Europe Non-Alcoholic Steatohepatitis market. However, issues associated with stringent regulations related to Non-Alcoholic Steatohepatitis the growth of Europe Non-Alcoholic Steatohepatitis market.

The Europe Non-Alcoholic Steatohepatitis market segmented into product, application, sales channel and country. Based on product type the Europe Non-Alcoholic Steatohepatitis market is segmented into vitamin e and pioglitazone, ocaliva, elafibranor, selonsertib, cenicriviroc, and others. The selonsertib & cenicriviroc segment is expected to be the fastest growing segment over the forecaste period..Based on application the Europe Non-Alcoholic Steatohepatitis market segmented into treatment and diagnosis. The treatment segment is dominated Europe Non-Alcoholic Steatohepatitis market in 2020. Based on sales channel the Europe Non-Alcoholic Steatohepatitis market segmented into hospital pharmacy, online provider, and retail pharmacy. The retail pharmacy segment is dominated EuropeNon-Alcoholic Steatohepatitis market in 2020. Based on country, the Europe Non-Alcoholic Steatohepatitis market segmented into Germany, U.K, France, Italy, Spain, Rest of Europe. The Germany is dominated the Europe Non-Alcoholic Steatohepatitis market in 2020.

Cadila Pharmaceutical,Intercept Pharmaceutical,Novartis AG,Galmed Pharmaceutical,GENFIT, ONE WAY LIVER SI, BioPredictive S.A.S, Siemens Healthineers AG and Laboratory Corporation of America Holdings are among the leading companies in the Europe Non-Alcoholic Steatohepatitis market. For instance, Nov-2021 GENFIT announced that its NIS4 technology has been recognized in a Stage 1 study1 undertaken by the Non-Invasive Biomarkers of Metabolic Liver Disease (NIMBLE) initiative of the Foundation for the National Institutes of Health’s Biomarkers Consortium as demonstrating a unique performance in identifying patients with “at-risk” Non-Alcoholic Steatohepatitis (NASH). The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in dynamic market.

TABLE OF CONTENTS

1. Introduction

1.1 Scope of the Study

1.2 The Insight Partners Research Report Guidance

1.3 Market Segmentation

1.3.1 Europe Non-Alcoholic Steatohepatitis Market – By Product

1.3.2 Europe lobal Non-Alcoholic Steatohepatitis Market – By Application

1.3.3 Europe Non-Alcoholic Steatohepatitis Market – By Sales Channel

1.3.4 Europe Non-Alcoholic Steatohepatitis Market – By Country

2. Key Takeaways

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. Europe Non-Alcoholic Steatohepatitis Market – Market Landscape

4.1 Overview

4.2 PEST Analysis

4.2.1 Europe PEST Analysis

4.3 Experts Opinion

5. Europe Non-alcoholic steatohepatitis (NASH) Market – Key Market Dynamics

5.1 Market Drivers

5.1.1 Rising Prevalence of NASH

5.1.2 Increasing Initiatives for the Awareness of NASH

5.2 Market Restraints

5.2.1 Lack of Established Guidelines in the Diagnosis and Management of NASH

5.2.2 Withdrawal of Drugs from Seeking Marketing Authorization for NASH

5.3 Market Opportunities

5.3.1 Growing Opportunities in Developing Nations

5.3.2 High Competition among Market Players to Manufacture the First Marketed NASH Drug Creates Global Sales Opportunity

5.4 Future Trends

5.4.1 Growing Clinical Trials Involving Combination Studies of Drugs

5.5 Impact Analysis

6. Non-alcoholic steatohepatitis (NASH) Market–Europe Analysis

6.1 Europe Non-Alcoholic Steatohepatitis Market Revenue Forecast and Analysis

7. Europe Non-alcoholic steatohepatitis (NASH) Market Revenue and Forecasts To 2028– by Product

7.1 Overview

7.2 Product Market Revenue and Forecast Analysis (US$ Mn)

7.3 Vitamin E and Pioglitazone

7.3.1 Overview

7.3.2 Vitamin E and Pioglitazone Revenue and Forecast to 2028 (US$ Mn)

7.4 Ocaliva

7.4.1 Overview

7.4.2 Ocaliva Revenue and Forecast to 2028 (US$ Mn)

7.5 Elafibranor

7.5.1 Overview

7.5.2 Elafibranor Revenue and Forecast to 2028 (US$ Mn)

7.6 Selonsertib & Cenicriviroc

7.6.1 Overview

7.6.2 Selonsertib Revenue and Forecast to 2028 (US$ Mn)

7.7 Others

7.7.1 Overview

7.7.2 Others Revenue and Forecast to 2028 (US$ Mn)

8. Europe Non-Alcoholic Steatohepatitis (NASH) Market Analysis and Forecast to 2028 – by Application

8.1 Overview

8.2 Application Market Revenue and Forecast Analysis (US$ Mn)

8.3 Treatment

8.3.1 Overview

8.3.2 Treatment Market Revenue and Forecast to 2028 (US$ Mn)

8.4 Diagnosis

8.4.1 Overview

8.4.2 Diagnosis Market Revenue and Forecast to 2028 (US$ Mn)

9. Europe Non-Alcoholic Steatohepatitis (NASH) Market Analysis and Forecast to 2028 – by Sales Channel

9.1 Overview

9.2 Sales Channel Market Revenue and Forecast Analysis (US$ Mn)

9.3 Hospital Pharmacy

9.3.1 Overview

9.3.2 Hospital Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)

9.4 Retail Pharmacy

9.4.1 Overview

9.4.2 Retail Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)

9.5 Online Provider

9.5.1 Overview

9.5.2 Online Provider Market Revenue and Forecast to 2028 (US$ Mn)

10. Europe Non-alcoholic steatohepatitis (NASH) Market Revenue and Forecasts to 2028 – Country Analysis

10.1 Europe: Non-alcoholic steatohepatitis (NASH) Market

10.1.1 Overview

10.1.3 Europe: Non-alcoholic steatohepatitis (NASH) Market, by Country, 2021 & 2028 (%)

10.1.3.1 Germany: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

10.1.3.1.1 Overview

10.1.3.1.2 Germany: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

10.1.3.1.3 Germany: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)

10.1.3.1.4 Germany: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)

10.1.3.1.5 Germany: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

10.1.3.2 France: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

10.1.3.2.1 Overview

10.1.3.2.2 France: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

10.1.3.2.3 France: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)

10.1.3.2.4 France: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)

10.1.3.2.5 France: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

10.1.3.3 UK: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

10.1.3.3.1 Overview

10.1.3.3.2 UK: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

10.1.3.3.3 UK: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)

10.1.3.3.4 UK: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)

10.1.3.3.5 UK: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

10.1.3.4 Italy: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

10.1.3.4.1 Overview

10.1.3.4.2 Italy: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

10.1.3.4.3 Italy: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)

10.1.3.4.4 Italy: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)

10.1.3.4.5 Italy: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

10.1.3.5 Spain: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

10.1.3.5.1 Overview

10.1.3.5.2 Spain: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

10.1.3.5.3 Spain: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)

10.1.3.5.4 Spain: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)

10.1.3.5.5 Spain: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

10.1.3.6 Rest of Europe: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

10.1.3.6.1 Overview

10.1.3.6.2 Rest of Europe: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

10.1.3.6.3 Rest of Europe: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)

10.1.3.6.4 Rest of Europe: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)

10.1.3.6.5 Rest of Europe: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

11. Industry Landscape

11.1 Overview

11.2 Organic Developments

11.2.1 Overview

11.3 Inorganic Developments

11.3.1 Overview

12. Company Profiles

12.1 Cadila Pharmaceuticals Ltd.

12.1.1 Key Facts

12.1.2 Business Description

12.1.3 Products and Services

12.1.4 Financial Overview

12.1.5 SWOT Analysis

12.1.6 Key Developments

12.2 Intercept Pharmaceuticals, Inc

12.2.1 Key Facts

12.2.2 Business Description

12.2.3 Products and Services

12.2.4 Financial Overview

12.2.5 SWOT Analysis

12.2.6 Key Developments

12.3 Novartis AG

12.3.1 Key Facts

12.3.2 Business Description

12.3.3 Products and Services

12.3.4 Financial Overview

12.3.5 SWOT Analysis

12.3.6 Key Developments

12.4 Galmed Pharmaceuticals.

12.4.1 Key Facts

12.4.2 Business Description

12.4.3 Products and Services

12.4.4 Financial Overview

12.4.5 SWOT Analysis

12.4.6 Key Developments

12.5 GENFIT.

12.5.1 Key Facts

12.5.2 Business Description

12.5.3 Products and Services

12.5.4 Financial Overview

12.5.5 SWOT Analysis

12.5.6 Key Developments

12.6 ONE WAY LIVER, S.L

12.6.1 Key Facts

12.6.2 Business Description

12.6.3 Products and Services

12.6.4 Financial Overview

12.6.5 SWOT Analysis

12.6.6 Key Developments

12.7 BioPredictive S.A.S

12.7.1 Key Facts

12.7.2 Business Description

12.7.3 Products and Services

12.7.4 Financial Overview

12.7.5 SWOT Analysis

12.7.6 Key Developments

12.8 Siemens Healthineers AG

12.8.1 Key Facts

12.8.2 Business Description

12.8.3 Products and Services

12.8.4 Financial Overview

12.8.5 SWOT Analysis

12.8.6 Key Developments

12.9 Laboratory Corporation of America Holdings

12.9.1 Key Facts

12.9.2 Business Description

12.9.3 Products and Services

12.9.4 Financial Overview

12.9.5 SWOT Analysis

12.9.6 Key Developments

13. Appendix

13.1 About The Insight Partners

13.2 Glossary of Terms

LIST OF TABLES.

Table 1. Germany: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)

Table 2. Germany: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)

Table 3. Germany: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

Table 4. France: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)

Table 5. France: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)

Table 6. France: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

Table 7. UK: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)

Table 8. UK: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)

Table 9. UK: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

Table 10.   Italy: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)

Table 11.   Italy: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)

Table 12.   Italy: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

Table 13.   Spain: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)

Table 14.   Spain: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)

Table 15.   Spain: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

Table 16.   Rest of Europe: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)

Table 17.   Rest of Europe: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)

Table 18.   Rest of Europe: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

Table 19.   Organic Developments Done By Companies

Table 20.   Inorganic Developments Done By Companies

Table 21.   Glossary of Terms

LIST OF FIGURES.

Figure 1. Europe Non-Alcoholic Steatohepatitis Market Segmentation

Figure 2. Europe Non-Alcoholic Steatohepatitis Market, By Country

Figure 3. Europe Non-Alcoholic Steatohepatitis Market Overview

Figure 4. Europe Non-Alcoholic Steatohepatitis Market, By Application

Figure 5. Europe Non-Alcoholic Steatohepatitis Market, By Country

Figure 6. Europe: PEST Analysis

Figure 7. Europe Experts Opinion

Figure 8. Europe Non-Alcoholic Steatohepatitis (NASH) Market Impact Analysis of Drivers and Restraints

Figure 9. Europe Non-Alcoholic Steatohepatitis Market– Revenue Forecast and Analysis

Figure 10.   Europe Product Market Analysis and Forecast 2021 and 2028 (%)

Figure 11.   Europe Vitamin E and Pioglitazone Revenue and Forecast to 2028 (US$ Mn)

Figure 12.   Europe Ocaliva Revenue and Forecast to 2028 (US$ Mn)

Figure 13.   Europe Elafibranor Revenue and Forecast to 2028 (US$ Mn)

Figure 14.   Europe Selonsertib Revenue and Forecast to 2028 (US$ Mn)

Figure 15.   Europe Others Revenue and Forecast to 2028 (US$ Mn)

Figure 16.   Europe Application Market Analysis and Forecast 2021 and 2028 (%)

Figure 17.   Europe Treatment Market Revenue and Forecast to 2028 (US$ Mn)

Figure 18.   Europe Diagnosis Market Revenue and Forecast to 2028 (US$ Mn)

Figure 19.   Europe Sales Channel Market Analysis and Forecast 2021 and 2028 (%)

Figure 20.   Europe Hospital Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)

Figure 21.   Europe Retail Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)

Figure 22.   Europe Online Provider Market Revenue and Forecast to 2028 (US$ Mn)

Figure 23.   Europe: Non-alcoholic steatohepatitis (NASH) Market, by Key Country – Revenue (2021) (US$ Million)

Figure 24.   Europe: Non-alcoholic steatohepatitis (NASH) Market, by Country, 2021 & 2028 (%)

Figure 25.   Germany: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

Figure 26.   France: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

Figure 27.   UK: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

Figure 28.   Italy: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

Figure 29.   Spain: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

Figure 30.   Rest of Europe: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

The List of Companies - Europe Non-Alcoholic Steatopatitis Market

● Cadila Pharmaceutical.

● Intercept Pharmaceutical.

● Novartis AG.

● Galmed Pharmaceutical.

● GENFIT.

● ONE WAY LIVER SI.

● BioPredictive S.A.S.

● Siemens Healthineers AG.

● Laboratory Corporation of America Holdings.

● Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe Non-Alcoholic Steatohepatitis market forecast.

● Highlights key business priorities in order to assist companies to realign their business strategies

● The key findings and recommendations highlight crucial progressive industry trends in Europe Non-Alcoholic Steatohepatitis market forecast, thereby allowing players across the value chain to develop effective long-term strategies

● Develop/modify business expansion plans by using substantial growth offering developed and emerging markets

● Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the non-alcoholic steatohepatitis, as well as those hindering it.

● Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.

TOP